Syngene International, a contract research organisation, has appointed Jonathan Hunt as CEO-designate.
Hunt is expected to take charge as CEO, after the retirement of current CEO Peter Bains in March 2016.
In his role, Hunt will be responsible for strengthening Syngene’s relations with its existing global customers as well as forging new relationships.
He will also steer the company’s investments in developing and strengthening its capabilities and capacities to augment Syngene’s service offerings.
Prior to Syngene, Hunt was with AstraZeneca where he held various leadership positions including President & Director of AstraZeneca, Austria, and President & COO, AstraZeneca India.
While Bains, who has worked closely with Syngene as a Director since 2010 and appointed CEO in February 2015, will continue as a member of the Syngene Board after his retirement.
Kiran Mazumdar-Shaw, Managing Director, Syngene International, said: “Hunt joins Syngene executive leadership team. This comes after the resounding success of IPO earlier during the year. Syngene is now at an exciting phase of its journey… Jonathan has a rich experience in the global biopharmaceutical industry and a proven track record of leading transformational change and delivering growth.”
“Under his leadership, Syngene will continue to strengthen its position in the global CRAMs market,” she added.
Bains said: “Syngene, with its differentiated strategy of multi-model integrated discovery, development and manufacturing capabilities, its expanding customer base and seasoned management team, is on a strong growth trajectory.”